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Modulation of renal hemodynamics by IGF-1 is absent in
spontaneously hypertensive rats
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Modulation of renal heniodynamics by IGF-1 is absent in spontane-
ously hypertensive rats. We recently reported that attenuation of vasoac-
tive agent-induced calcium signal and cell contraction of mesangial cell by
insulin-like growth factor I (IGF-1), observed in normal mesangial cells, is
totally abolished in spontaneously hypertensive rat (SHR) mesangial cells.
This phenomenon might be related to the well-known aberrant regulation
of SHR glomerular hemodynamics. Since it has been reported that in vivo
IGF-1 infusion increases renal plasma flow (RPF) and glomerular filtra-
tion rate (GFR), we examined whether the modulation of renal function
by IGF-l is altered in SHR. We performed in vivo renal clearance studies
using eight-week-old SHR and control Wistar Kyoto rats (WKY) before
and after IGF-1 (5 gIkg) infusion into the left renal artery for 20 minutes.
Mean arterial pressure was not affected by IGF-1 in both WKY and SHR.
In WKY, IGF-1 increased GFR and RPF, and decreased renal vascular
resistance (RVR). However, GFR, RPF, and RVR were not altered by
IGF-1 in SHR, while systemic infusion of angiotensin II antagonist,
CV-11974, increased GFR and RPF. The present data show that the
modulation of renal hemodynamics by IGF-I is absent in SHR. This might
be related the pathophysiology of the development of hypertension.
Many observations indicate that the kidney plays an important
role in the evolution of hypertension. The most convincing
evidence for the role of the kidney in the development of
hypertension is shown in cross transplantation experiments. Fly-
pertension developed in the Fl hybrids of spontaneously hyper-
tensive rats (SHR) and Wistar Kyoto rats (WKY) when they
received a kidney transplant from SHR, while hypertension did
not develop when they received a kidney transplant from WKY [1,
2]. Similar results were reported in other hypertensive animal
models, such as Milan hypertensive rats and DahI salt-sensitive
(DS) rats [3, 4]. Moreover, in humans it has been reported that
renal transplantation from normotensive donors ameliorated hy-
pertension in the patients on dialysis due to hypertensive neph-
rosclerosis [5]. These findings strongly suggest that the intrinsic
aberration in the regulation of renal function underlies the
pathogenesis of hypertension. Indeed, altered regulation of renal
function has been shown by many investigators, which includes
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enhanced tubuloglomerular feedback [6] and abnormal glomeru-
lar pressure-filtration curve [7—9].
Previously we reported that the functions of glomerular mes-
angial cells from genetically hypertensive rats may differ from
normal rat-derived mesangial cells. In SHR and DS rats, attenu-
ation of normally present modulation of mesangial cell function
by ambient chloride (Cl) concentration was absent [10, 11].
Moreover, we have recently shown that in SHR mesangial cells,
suppression of vasoaetive agent-induced responses by insulin-like
growth factor I (IGF-1) receptor activation [12], which is observed
in normotensive WKY mesangial cells, is totally abolished [13].
Since mesangial cells are believed to play a major role in the
regulation of glomerular hemodynamics, disturbed mesangial cell
function might cause aberrant renal function, which underlies the
pathophysiology of hypertension and abnormal body fluid status.
It is known that systemic infusion of IGF-1 increased glomer-
ular filtration rate (GFR) [14]. This modulation of glomerular
function by IGF-1 might be at least partially explained by its effect
on glomerular mesangial cells, since vasoactive agent-induced
calcium (Ca) signal and cell contraction were attenuated by IGF-1
receptor activation in normal mesangial cells [12]. This, together
with our observation on the lack of IGF-1 effects in SHR
mesangial cells mentioned above, suggests the possibility that
renal hemodynamic responses to IGF-1 infusion might be altered
in SHR. Therefore, in the present study, we directly infused IGF-1
into the renal artery of SHR to examine whether or not the SHR
kidney responds differently from normal WKY kidney.
METHODS
Renal clearance study
Clearance studies were performed on anesthetized, adult male
SHR at the age of eight weeks and age-matched WKY as controls
weighing 200 to 240 g, which were prepared according to proto-
cols described previously [15]. In brief, following mactin anesthe-
sia (100 mg/kg body wt, intraperitoneally), the left femoral artery
was catheterized with SP-37 polyethylene catheters that was used
to monitor mean systemic arterial pressure (MAP) by means of a
pressure transducer (FD pickup TB-61 iT; Nihon Kohden, Tokyo,
Japan) connected to a direct writing recorder (Nihon Kohden),
and for blood sampling. Following a tracheotomy, SP-37 polyeth-
ylene catheters were inserted into both jugular veins for infusion
of plasma, inulin and para-aminohippuric acid (PAH; inulin and
PAH, 7.5 and 1.6% solution, respectively, in 0.9% NaCI at 1.2
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Table 1. Basal renal hemodynamics, MAP, and hematocrit in SHR and
WKY
WKY SHR P value
MAP, mm Hg
Hct, %
GFR, mI/mm
RPF, mI/mm
RVR, mm Hg/mI/mm
Numbers of rats
103.8 9.2
44.8 1.7
0.69 0.09
1.71 0.18
34.8 5.0
5
143.3 24.6
46.3 2.5
1.10 0.25
2.45 0.74
34.9 15.8
5
<0.01
NS
<0.01
NS
NS
The values are means SD.
ml/hr), and other experimental solutions. The left kidney was
exposed by a left subcostal incision, and separated from the
surrounding fat. A 30-gauge needle was placed in the abdominal
aorta at the take-off of the left renal artery through which a
maintenance infusion of 0.9% NaCl was initiated at the rate of
0.025 mI/mm. Homologous rat plasma was administered intrave-
nously at the rate of 10 mi/kg body wt/hr for 45 minutes, followed
by a reduction in infusion rate to 1.5 mI/kg body wt/hr for the
remainder of the experiment. This protocol has been shown
previously to adequately replace surgically-induced plasma losses,
thus maintaining euvolemia [16].
In all experiments, measurements were started at 60 minutes.
After the onset of plasma infusion and carried out as follows: two
or three samples of urine from the experimental kidney were
collected, each over 15 minutes, for the determination of flow
rate, inulin and PAH concentration, and for the calculation of
whole kidney GFR and renal plasma flow (RPF). For these urine
collections, indwelling ureteral catheters (SP-10) were used. Sam-
pies of femoral arterial blood (0.1 ml each) were obtained at the
midpoint of each two urine collection period for determination of
hematocrit (Hct) and plasma concentration of inuiin and PAH.
Whole kidney inulin and PAH clearances were performed during
the baseline conditions, and repeated during or after the admin-
istration of the experimental compounds as specified below.
Experiments were performed in two protocols as follows:
Protocol 1. After two consecutive 15-minute control urine
collections, 5 j.tg/kg body wt IGF-1 in isotonic saline was infused
into the left renal artery for 20 minutes. Then IGF-1 infusion into
the left renal artery was stopped by changing the infusate to
isotonic saline without IGF-1, and two consecutive 15-minute
urine collections were made. Blood samples were drawn from the
catheter in the left femoral artery at the midpoint of each of the
two urine collection periods.
Protocol 2. After two consecutive 15-minute control urine
collections, 0.01 mg/kg body wt CV-11974, a nonpeptidic angio-
tensin 11 antagonist [171, was added into the systemic infusion.
After CV-11974 infusion, two consecutive 15-minute control urine
collections were made. Blood samples were similarly drawn at the
midpoint of each of the two urine collection periods as Protocol 1.
Blood and urine samples were analyzed for inulin and PAH as
reported previously [18]. Hct, measured for each blood samples,
did not change at all through the experiment, indicating that the
volume state of the experimental rat was constant. Plasma con-
centrations of IGF-1, insulin, and glucagon were measured by
radioimmunoassay, and plasma glucose with the Gluc-DH
method [19].
GFR was calculated as inulin clearance, and RPF was calcu-
Pre Post Pre Post
WKY SHR
Fig. 1. Effects of IGF-1 infusion into renal artery on MAP in WKY and
SHR. MAP was not affected by IGF-1 infusion in both WKY and SHR,
although the basal MAP was significantly higher in SHR than in WKY.
The values are means SD of 5 independent experiments. < 0.01
versus the value of WKY. The individual pairs of data before and after the
infusion of IGF-1 are shown by closed circles and connected with solid
lines.
lated as PAH clearance. Renal vascular resistance (RVR) was
calculated from RPF, Hct, and MAP.
Materials
IGF-1 was purchased from GIBCO BRL (Gaithersburg, MD,
USA). CV-11l974 was a product of Takeda Chemical Industries
(Osaka, Japan).
Statistics
All results are expressed as means SD. Statistical analysis was
performed using the paired or unpaired t-test analysis. P values
less than 0.05 were considered significant.
RESULTS
Renal hemodynamic study
Values for basal renal hemodynamics, MAP, and Hct in WKY
and SHR are shown in Table 1. The MAP in SHR was signifi-
cantly higher than that in WKY (143.3 24.6 vs. 103.8 9.2 mm
Hg; N = 5, P < 0.01). There was no difference in Hct between
SHR and WKY (46.3 2.5 vs. 44.8 1.7%; N = 5, NS). GFR was
significantly increased in SHR compared with WKY (1.10 0.25
vs. 0.69 0.09 mI/mm; N = 5, P < 0.01). RPF was slightly but not
significantly increased in SHR compared with WKY (2.45 0.74
vs. 1.71 0.18 mI/mm; N = 5, NS). RVR in SHR was almost
identical to that in WKY (34.9 15.8 vs. 34.8 5.0 mm
Hg/mI/mm; N = 5, NS).
Effects of IGF-1 on the kidney
As shown in Figure 1, there was no change in MAP before and
after the administration of IGF-1 into the renal artery in both
WKY and SHR. In WKY, infusion of IGF-1 into the renal artery
significantly increased GFR from 0.69 0.09 to 1.00 0.22
mI/mm (N = 5,P < 0.01) and RPF from 1.71 0.18 to 2.45 0.42
mi/mm (N = 5, P < 0.01), and decreased RVR from 34.8 5.0 to
23.9 5.1 mm Hg/mi/mm (N = 5, P < 0.01; Fig. 2). By contrast,
GFR, RPF, and RVR did not change after infusion of IGF-1 into
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the renal artery in SHR (GFR from 1.10 0.25 to 1.15 0.23
mi/mm; RPF from 2.45 0.74 to 2.42 0.59 mi/mm; RVR from
34.9 15.8 to 34.0 13.9 mm Hg/mi/mm; N = 5, Fig. 3).
Effects of IGF-1 on plasma levels of glucose, IGF.1, insulin,
and glucagon
In WKY, plasma levels of glucose, IGF-1, and ghicagon were
not affected by IGF-1 infusion. The plasma level of insulin was
slightly decreased by IGF-1 infusion, but the change was not
significantly different (Fig. 4). Similar results were obtained in
SHR (Fig. 5). Plasma levels of glucose and IGF-1 were not altered
by IGF-1 infusion. Plasma levels of insulin and glucagon were
slightly decreased by IGF-1 infusion, but the change was not
significantly different.
Effects of' CV-11974 on the kidney
Similar to some observations reported by other investigators 12,
20—22], the GFR of SHR was higher than that of WKY in the
strain of rats used in the present study. It is possible that GFR and
RPF had already reached maximum values at the baseline condi-
tion in SHR, and thus the SHR could not respond to IGF-1. To
exclude this possibility, we examined the effects of systemic
infusion of CV-1 1974, a nonpeptidic angiotensin II antagonist
[17], on renal hemodynamics in SHR. As shown in Figure 6,
CV-11974 significantly increased GFR (from 0.90 0.15 to
1.36 0.11 mI/mm; N 5, P < 0.01) and RPF (from 1.91 0.45
to 3.46 0.51 ml/min; N = 5, P < 0.01), and decreased RVR
(from 39.0 9.3 to 18.0 3.4 mm Hg/mI/mm; N = 5, P < 0.01)
in SHR, although MAP was significantly decreased by systemic
infusion of CV-11974 (from 135.5 12.3 to 111.6 13.3 mm Hg;
N = 5, P < 0.01). This indicates that basal GFR and RPF of SHR
had not been maximally increased and could be up-regulated by a
pharmacological or physiological intervention.
DISCUSSION
The present study has reproduced the results of a previous
report by Hirschberg et al, which found that IGF-1 infusion can
increase RPF and GFR in normotensive WKY [14]. The present
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Fig. 2. Effects of IGF-1 infusion into renal
artery on GFR, RPF, and RVR in WKY.
Infusion of IGF-1 into renal artery significantly
increased GFR and RPF, and decreased RVR
in WKY. The values are means so of 5Pre Post Pre Post independent experiments. *P < 0.01 versus the
value before IGF-1 infusion. The individualRPF RVR pairs of data before and after the infusion of
IGF-1 are shown by closed circles and
WKY connected with solid lines.
Fig. 3. Effects of IGF-1 infusion into renal
artery on GFR, RPF, and RVR in SHR. GFR,
RPF, and RVR were not altered by IGF-1
Pre Post infusion into renal artery in SHR. The values
are means SD of 5 independent experiments.
RVR The individual pairs of data before and after
the infusion of IGF-1 are shown by closed
circles and connected with solid lines.
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Fig. 4. Effects of IGF-1 infusion on plasma
levels of glucose, IGF-1, insulin, and glucagon
in WKY. Plasma levels of glucose, IGF-1, and
glucagon were not altered by IGF-1 infusion.
Plasma level of insulin was slightly but not
significantly decreased by IGF-1 infusion. The
values are means SD of 5 independent
experiments.
study also clearly indicates that hemodynamic changes caused by
IGF-1 are due to the specific alteration of renal function, because,
in the present study, IGF-1 was directly infused into the renal
artery. Furthermore, systemic concentration of IGF-1 did not
change detectably after IGF-l infusion and there was no change in
blood pressure, indicating that IGF-1 infusion had no systemic
effect. However, as shown in Figure 2, RVR markedly decreased
in response to IGF-1 infusion, leading to parallel increases in RPF
and GFR by as much as 45%. It was also ascertained that this
effect of IGF-1 is not secondary to systemic changes in glucose,
glucagon or insulin. Therefore, IGF-1 specifically induces direct
renal hemodynamic changes and causes an increase in RPF and
GFR in normal rats.
In clear contrast to normotensive WKY, IGF-1 failed to cause
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Fig. 6. Effects of CV-11974 on MAP, GFR,
RPF, and RVR in SHR. Systemic infusion of
CV-11974, a nonpeptidic angiotensin II
antagonist, significantly increased GFR and
RPF, and decreased RVR in SHR, although
MAP was significantly decreased by CV-11974.
The values are means st of 5 independent
Pre Post Pre Post experiments. *P < 0.01 versus the value before
infusion of CV-11974. The individual pairs of
RPF RVR data before and after the infusion of CV-1 1974
are shown by closed circles and connected with
solid lines.
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renal hemodynamic changes in SHR kidney. Marked decrease in
RVR and increase in RPF and GFR observed in WKY were
absent in SHR. The reasons for these discrepant responses of
WKY and SHR to IGF-1 are not clear. One possibility is the
presence of a high level of basal vasoconstrictive tone in WKY
and its absence in SHR, and thus only WKY could respond to the
vasorelaxing effects of IGF-1. To exclude this possibility, the
effects of another vasorelaxing agent, CV-11974, an angiotensin
type 1 receptor antagonist [17], was examined in SHR. In spite of
the defective modulation of renal hemodynamics by IGF-1, the
blockade of angiotensin II action through angiotensin type 1
receptor by CV-11974 increased RPF and GFR up to 50% in
SHR, changes similar to IGF-1 in normal WKY, although sys-
temic blood pressure was slightly decreased. Thus, in SHR, the
ability of the kidney to respond to IGF-1 is absent, while the
ability to increase RPF or GFR in response to other agents, such
as in this particular series of experiments, CV-1 1974, is main-
tained. This indicates that a certain level of basal vasoconstrictive
tone was present in SHR and that IGF-1 specifically failed to
revert it.
The mechanism underlying this discrepant renal responses to
IGF-1 infusion is not known at present but is intriguing. We
recently showed that IGF-1 receptor activation attenuated the cell
Ca signal and cell contraction by vasoactive agents of glomerular
mesangial cells derived from normotensive rats, including Wistar
rats, Dahi salt-resistant rats, and WKY [11—13], but this attenua-
tion was completely absent in SHR mesangial cells [13]. These
different modulations of mesangial cell function between WKY
and SHR might explain the discrepant renal hemodynamic change
in vivo by IGF-1 observed in WKY and SHR in the present paper.
In our recent paper examining the effects of IGF-1 on mesan-
gial cell function [12], we proposed the possibility that the
modulation of glomerular hemodynamics by IGF-1 is partly
through the effect of IGF-1 on mesangial cell function. Thus,
mesangial cell relaxation induced by IGF-1 might cause intraglo-
merular hemodynamic change including increased ultrafiltration
coefficient (K1) of the glomerulus. Indeed, Hirschberg et al
directly examined the parameters of glomerular hemodynamics
and reported that Kf increased in response to IGF-1 infusion [14].
In addition, there may be a difference in the responsiveness to
IGF-1 between SHR and WKY in the cells composing renal
vasculature, namely vascular smooth muscle cells (VSMC) and
vascular endothelial cells. As is clearly shown in both the previous
study by.Hirschberg et al [14] and the present study (Fig. 2), the
decrease in RVR was caused by IGF-1 in normal rats, indicating
that the normal renal vascular system is affected by IGF-1.
A micropuncture study by Hirschberg et al revealed that IGF-1,
in addition to causing a decrease in K1, significantly decreased
efferent arteriolar resistance. They also showed that there was a
tendency for a decrease of afferent arteriolar resistance [14]. Since
afferent and efferent arterioles are the major resistant arteries of
kidney and important determinants of glomerular hemodynamics,
it is possible that IGF-1-induced relaxation of afferent and
efferent arterioles is lacking in SHR, and 1GF-1 failed to decrease
RVR. This defect of SHR might be due to the abnormality of
afferent and efferent arteriolar VSMC per Se, that is, the unre-
sponsiveness of VSMC to IGF-1 in SHR.
It is also possible that it could be due to the altered respon-
siveness of mesangial cell to IGF-1 in SHR [13], as briefly
discussed above. It is well known that mesangial cells produce and
release various vasoactive agents, such as prostaglandins [10],
which are believed to act in a paracrine manner. Extraglomerular
mesangial cells reside in close contact with afferent and efferent
arterioles [23, 24], and it is possible that an extraglomerular
mesangial cell function modulates these arteriolar functions.
Therefore, abnormal mesangial cell response to IGF-1 in SHR
may lead to an abnormal afferent and efferent arteriolar response
even if VSMC of arterioles are not aberrant.
Also, endothelial cell function may be altered in SHR and this
could explain the present observation. Specific receptors for
IGF-1 were identified on glomerular endothelial cells [25] and
endothelial cells produce nitric oxide, a potent vasorelaxant and
possible cellular mediator of IGF-1 action [26]. Thus, it is possible
that altered nitric oxide production by endothelial cells in SHR is
related to the lack of IGF-1 effect in SHR. However, this
possibility was not examined in the present study. There are
accumulating data indicating SHR hemodynamics are abnormally
regulated. The presence of a defect in renal hemodynamics in
SHR shown in the present study is a further addition to the
previously known defects in renal hemodynamics of hypertensive
rat models, such as disturbed tubuloglomerular feedback and
altered pressure diuresis curve. However, the exact physiological
significance of these defects in the development of hypertension is
not known. The present findings that SHR kidney failed to
increase RPF and GFR in response to vasorelaxing IGF-1 infu-
sion suggest that kidney of SHR may have exaggerated renal
vasoconstriction, thus in contrast to WKY, SHR kidney could not
modulate glomerular heniodynamics properly under various con-
ditions, such as volume expansion or an elevation in systemic
blood pressure. This alteration may have some significance in the
pathophysiology of hypertension.
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